1Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothedial cells. Circulation, 2000, 102 (18):2165-2168.
2Pasceri V, Cheng JS, Willerson JT, et al. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation, 2001, 103 (21):2531-2534.
3Kobayashi S, Inoue N, Ohashi Y, et al. Interaction of oxidative stress and inflammatory response in coronary plague instability. Arterioscler Thromb Vasc Biol, 2003, 23 (8): 1398-1404.
4Ikonomidis I, Adreotti F, Economou E, et al. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation, 1999, 100 (8): 793-798.
5Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin,and the risk of cardiovascular disease in apparently healthy men. N Engl J Med, 1997, 336 (14): 973-979.
6Azar RR, Klayme S, Germanos M, et al. Effects of aspirin(325mg/day) on serum high-sensitivity C-reactive protein, cytokines, and adhersion molecules in healthy volunteers. Am J Cardiol,2003,92(2) :236-239.
7Feldman M, Jialal Ⅰ, Devaraj S, et al. Effects of low-dose aspirin on serum C-reactive protein and thromboxane B2 concentrations: a placebocontrolled study using a highly sensitive C-reactive protein assay. J Am Coll Cardiol, 2001, 37 (8): 2036-2041.
8Takeda T, Hoshida S, Nishino M, et al. Relationship between effects of statins, aspirin and angiotensin Ⅱ modulators and high-sensitive C-reactive protein levels. Atherosclerosis, 2003, 169 (1): 155-158.
9Chan AW, Bhatt DL, Chew DP , et al. Relation of inflammation and benefit of statins after percutaneons coronary interventions. Circulation,2003, 107 (13): 1750-1756.
10Lawten WB, Khan QA. Usefulness of quinapril and irbesartan to improve the anti-inflammatory response of atorvastatin and aspirin in patients with coronary heart disease. Am J Cardiol, 2003, 91 (9): 1116-1119.
6SERRUYS PW, DE FEYTER P, MACAYA C, et al. Fluvastafin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial [J]. JAMA, 2002, 287(24): 3215-3222.
7ROSS R. Atherosclerosis is an inflammation disease[J]. Am Heart J, 1999, 158: 419--420.
8OUCHI N, KIHARA S, FUNAHASHI T, et al. Obestity, adiponectin and vascular inflammatory disease [J]. Lipidology, 2003, 14(6): 561-566.
9OUCHI N, KIHARA S, ARITA Y, et al. Adiponectin, an adipocyte-derlved plasma protein, inhibits endothelial NF-kappaB signaling through a c-AMP-dependent pathway [J]. Circulation, 2000, 102(11): 1296-1301.
10The Scandinavian Simvastatin Survival Study Group. Randomize1 tried of cholesterol lowering in 4444 patients with coronary heart diseases: the scandinavian sinvastatin survival study (4s) [J]. Lancet, 199,1, 344: 1383.
